

Notes to Editors

Morphotek's Pipeline:

Phase	MORAb ID	Antibody Type	Target / Application
Phase I	MORAb-009	Humanized IgG1 antibody	Pancreatic/ Lung cancer
Preclinical (IND preparation)	MORAb-004	IgG1 antibody	Melanoma/ Neovascular disease
Preclinical (IND preparation)	MORAb-022	Humanized IgG1 antibody	Autoimmune diseases
Preclinical	MORAb-028	Fully human IgG1 monoclonal antibody	Autoimmune diseases
		Fully human IgG1 monoclonal antibody	Autoimmune diseases
		Therapeutic antibody	
		Therapeutic antibody	

®

Human MORPHODOMA[®] is able to generate fully human monoclonal antibodies. Furthermore, through the application of its proprietary technology and know-how, Morphotek is able to optimize the titer of its cell-lines, effect class switching, and enhance antibody affinity.

About Libradoma[™]

The Libradoma[™] technology process utilizes Human MORPHODOMA[®] and other propriety technologies to generate libraries potentially comprised of thousands of hybridomas that can be rapidly screened using high-throughput robotics to identify hybridomas expressing human antibodies with target affinity profiles.